Sunho Biologics, Inc. (HKG:2898)
Hong Kong
· Delayed Price · Currency is HKD
6.40
0.00 (0.00%)
At close: Mar 10, 2026
Sunho Biologics Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Other Revenue | 0.02 | 0.04 | 17.53 | 1.85 | 3.22 |
| Revenue | 0.02 | 0.04 | 17.53 | 1.85 | 3.22 |
| Revenue Growth (YoY) | -99.85% | -99.78% | 847.78% | -42.48% | - |
| Gross Profit | 0.02 | 0.04 | 17.53 | 1.85 | 3.22 |
| Selling, General & Admin | 27.68 | 30.28 | 40.7 | 5.56 | 5.8 |
| Research & Development | 62.18 | 71.12 | 43.04 | 53.17 | 64.03 |
| Other Operating Expenses | - | - | 0.07 | 1.26 | - |
| Operating Expenses | 89.86 | 101.39 | 83.81 | 59.99 | 69.83 |
| Operating Income | -89.84 | -101.36 | -66.28 | -58.14 | -66.62 |
| Interest Expense | -1.18 | -0.92 | -0.69 | -5.07 | -4.17 |
| Interest & Investment Income | 12.72 | 9.45 | 3.47 | 0.02 | 0.01 |
| Currency Exchange Gain (Loss) | -0.04 | 3.84 | -8.29 | 0.03 | -0 |
| Other Non Operating Income (Expenses) | -2.72 | 9.02 | -60.91 | 11.18 | 0.01 |
| EBT Excluding Unusual Items | -81.07 | -79.97 | -132.7 | -51.99 | -70.78 |
| Gain (Loss) on Sale of Investments | -1.02 | - | - | - | 0.15 |
| Pretax Income | -82.09 | -79.97 | -132.7 | -51.99 | -70.63 |
| Net Income | -82.09 | -79.97 | -132.7 | -51.99 | -70.63 |
| Net Income to Common | -82.09 | -79.97 | -132.7 | -51.99 | -70.63 |
| Shares Outstanding (Basic) | 151 | 128 | 93 | 91 | 91 |
| Shares Outstanding (Diluted) | 151 | 128 | 93 | 91 | 91 |
| Shares Change (YoY) | 51.27% | 38.04% | 2.07% | - | - |
| EPS (Basic) | -0.54 | -0.62 | -1.43 | -0.57 | -0.78 |
| EPS (Diluted) | -0.54 | -0.62 | -1.43 | -0.57 | -0.78 |
| Free Cash Flow | -65.98 | -148.39 | -41.68 | -36.03 | -58.17 |
| Free Cash Flow Per Share | -0.44 | -1.16 | -0.45 | -0.40 | -0.64 |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Operating Margin | -528488.23% | -266723.68% | -378.00% | -3142.54% | -2071.39% |
| Profit Margin | -482864.71% | -210434.21% | -756.82% | -2810.16% | -2196.27% |
| Free Cash Flow Margin | -388135.29% | -390505.26% | -237.73% | -1947.30% | -1808.71% |
| EBITDA | -82.77 | -94.41 | -59.88 | -51.54 | -64.21 |
| D&A For EBITDA | 7.08 | 6.95 | 6.4 | 6.6 | 2.4 |
| EBIT | -89.84 | -101.36 | -66.28 | -58.14 | -66.62 |
Source: S&P Capital IQ. Standard template.
Financial Sources.